vs

Side-by-side financial comparison of Gauzy Ltd. (GAUZ) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Gauzy Ltd. is the larger business by last-quarter revenue ($20.1M vs $19.6M, roughly 1.0× STANDARD BIOTOOLS INC.). Gauzy Ltd. runs the higher net margin — -53.5% vs -177.4%, a 123.9% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (-11.5% vs -17.8%). Gauzy Ltd. produced more free cash flow last quarter ($-7.5M vs $-23.1M).

Gauzy Ltd. is a technology firm specializing in advanced liquid crystal-based smart glass solutions. Its product portfolio includes switchable light control films, adaptive glass, and integrated sensing systems, serving core markets of automotive manufacturing, construction, and consumer electronics globally.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

GAUZ vs LAB — Head-to-Head

Bigger by revenue
GAUZ
GAUZ
1.0× larger
GAUZ
$20.1M
$19.6M
LAB
Growing faster (revenue YoY)
LAB
LAB
+6.4% gap
LAB
-11.5%
-17.8%
GAUZ
Higher net margin
GAUZ
GAUZ
123.9% more per $
GAUZ
-53.5%
-177.4%
LAB
More free cash flow
GAUZ
GAUZ
$15.6M more FCF
GAUZ
$-7.5M
$-23.1M
LAB

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
GAUZ
GAUZ
LAB
LAB
Revenue
$20.1M
$19.6M
Net Profit
$-10.7M
$-34.7M
Gross Margin
21.4%
48.5%
Operating Margin
-62.4%
-168.5%
Net Margin
-53.5%
-177.4%
Revenue YoY
-17.8%
-11.5%
Net Profit YoY
53.5%
-28.8%
EPS (diluted)
$-0.57
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GAUZ
GAUZ
LAB
LAB
Q3 25
$19.6M
Q2 25
$20.1M
$21.8M
Q1 25
$40.8M
Q3 24
$22.1M
Q2 24
$24.4M
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
GAUZ
GAUZ
LAB
LAB
Q3 25
$-34.7M
Q2 25
$-10.7M
$-33.5M
Q1 25
$-26.0M
Q3 24
$-26.9M
Q2 24
$-23.1M
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
GAUZ
GAUZ
LAB
LAB
Q3 25
48.5%
Q2 25
21.4%
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
27.0%
46.1%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
GAUZ
GAUZ
LAB
LAB
Q3 25
-168.5%
Q2 25
-62.4%
-118.1%
Q1 25
-80.8%
Q3 24
-120.9%
Q2 24
-32.5%
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
GAUZ
GAUZ
LAB
LAB
Q3 25
-177.4%
Q2 25
-53.5%
-153.7%
Q1 25
-63.8%
Q3 24
-122.0%
Q2 24
-94.6%
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
GAUZ
GAUZ
LAB
LAB
Q3 25
$-0.09
Q2 25
$-0.57
$-0.09
Q1 25
$-0.07
Q3 24
$-0.07
Q2 24
$-2.60
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GAUZ
GAUZ
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$1.2M
$129.4M
Total DebtLower is stronger
$44.0M
Stockholders' EquityBook value
$17.9M
$399.7M
Total Assets
$136.8M
$539.6M
Debt / EquityLower = less leverage
2.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GAUZ
GAUZ
LAB
LAB
Q3 25
$129.4M
Q2 25
$1.2M
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$63.7M
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
GAUZ
GAUZ
LAB
LAB
Q3 25
Q2 25
$44.0M
Q1 25
Q3 24
$55.2M
Q2 24
$35.4M
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
GAUZ
GAUZ
LAB
LAB
Q3 25
$399.7M
Q2 25
$17.9M
$424.5M
Q1 25
$454.6M
Q3 24
$489.3M
Q2 24
$63.4M
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
GAUZ
GAUZ
LAB
LAB
Q3 25
$539.6M
Q2 25
$136.8M
$557.0M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$193.1M
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
GAUZ
GAUZ
LAB
LAB
Q3 25
Q2 25
2.46×
Q1 25
Q3 24
0.11×
Q2 24
0.56×
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GAUZ
GAUZ
LAB
LAB
Operating Cash FlowLast quarter
$-3.9M
$-22.2M
Free Cash FlowOCF − Capex
$-7.5M
$-23.1M
FCF MarginFCF / Revenue
-37.5%
-118.1%
Capex IntensityCapex / Revenue
18.2%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GAUZ
GAUZ
LAB
LAB
Q3 25
$-22.2M
Q2 25
$-3.9M
$-20.7M
Q1 25
$-30.3M
Q3 24
$-27.9M
Q2 24
$-15.7M
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
GAUZ
GAUZ
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-7.5M
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-20.0M
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
GAUZ
GAUZ
LAB
LAB
Q3 25
-118.1%
Q2 25
-37.5%
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-82.0%
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
GAUZ
GAUZ
LAB
LAB
Q3 25
4.5%
Q2 25
18.2%
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
17.8%
8.6%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GAUZ
GAUZ

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons